Octreoscan perspectives in sarcoidosis and idiopathic interstitial pneumonia

European Review for Medical and Pharmacological Sciences

Volumn 7, Issue 4, 2003, Pages 97-105

  Carbone, R ^a   Filiberti, R ^b   Grosso, M ^c   Paredi, P ^d   Peano, L ^e   Cantalupi, D ^a   Villa, G ^f   Monselise, A ^g   Bottino, G ^c   Shah, P ^d  

^a Regional Hospital   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e Statistical Analysis Regional Hosp   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dyspnea; HRCT; Idiopathic interstitial pneumonia; Idiopathic pulmonary fibrosis; Octreotide scintigraphy; Sarcoidosis; Somatostatin receptor scintigraphy

Indexed keywords

PENTETREOTIDE; PENTETREOTIDE IN 111;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DYSPNEA; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; LUNG SCINTISCANNING; MALE; MEDICAL ASSESSMENT; PATIENT MONITORING; PHYSICAL EXAMINATION; PREDICTION; SCORING SYSTEM; SEROLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; THORACOSCOPY; THORAX RADIOGRAPHY;

ADULT; AGED; DYSPNEA; EVALUATION STUDIES; FORECASTING; GALLIUM RADIOISOTOPES; HUMANS; INJECTIONS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OCTREOTIDE; RADIOGRAPHY, THORACIC; SARCOIDOSIS; TOMOGRAPHY, X-RAY;

EID: 10744228530     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wells AU, Du Bois RM. Prediction of disease progression in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 637-639.
2. Stirling RG, Cullinan P, Du Bois RM. Sarcoidosis. In: Schwarz MI, King TE Jr, eds. Interstitial Lung Disease. Hamilton, Ontario: BC Decker Inc., 1998; 279-323.
3. Turner-Warwick M, Mc Allister W, Lawrence R, Britten A, Haslam PL. Corticosteroid treatment in sarcoidosis: do serial lavage lymphocyte counts, serum-angiotensin-converting enzyme measurements, and gallium-67 scan help management? Thorax 1986; 41: 903-913.
4. Cushley MJ, Davison AG, Du Bois RM, et al. The diffuse parenchymal lung disease group: the diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54 (Suppl 1): S1-14.
5. Webb WR, Müller NL, Naidich DP. Clinical utility of high-resolution computed tomography. In: Webb WR, Müller NL, Naidich DP, eds. High-resolution CT of the lung. 3nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001; 569-597.
6. Remy-Jardin M, Giraud F, Remy J, et al. Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology 1994; 191: 675-680.
7. Brown KK. Current management of idiopathic pulmonary fibrosis and predictors of outcome. In: King TE Jr, ed. New approaches to managing idiopathic pulmonary fibrosis. San Francisco CA: American Thoracic Society, 2000; S21-26.
8. Arawaka H, Webb WR, McCowin M, Katsou G, Lee KN, Seitz RF. Inhomogeneous lung attenuation at thin-section CT: diagnostic value of expiratory scan. Radiology 1998; 206: 89-94.
9. Wells AU, Rubens MB, Dubois RM, et al. Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Eur Respir J 1997; 10: 280-285.
10. Cherniack RM, Colby TV, Flint A, et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 1180-1188.
11. Coxson HO, Hogg JC, Mayo JR, et al. Quantification of idiopathic pulmonary fibrosis using computed tomography and histology. Am J Respir Crit Med 1997; 155: 1649-1656.
12. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis. Am J Roentgenol 1997; 169: 977-983.
13. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994; 150: 462-468.
14. Agusti C, Xaubet A, Luburich P, Ayuso MC, Roca J, Rodriguez-Roisin R. Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis. Thorax 1996; 51: 841-845.
15. Leung AN, Brauner MW, Caillat-Vigneron N, Valeyre D, Grenier P. Sarcoidosis activity: correlation of HRCT findings with those of 67 Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay. J Comput Assist Tom 1998; 22: 229-234.
16. Carbone RG, Musi M, Cantalupi DP, et al. Somatostatin receptor versus Gallium-67 scintigraphy in interstitial lung diseases. Chest 1999; 119: 315S.
17. Lebthai R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and Gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42: 21-26.
18. Carbone R, Privitera V, Silvestri G, Cantalupi D, Filiberti R. Bottino G. Could be Octreoscan the gold standard in the assessment of Interstitial Lung Disease? Am J Respir Crit Care Med 2003; 167: 982S.
19. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Care Med 2000; 161: 646-664.
20. Raghu G. Evolving definition and approach to diagnosis of idiopathic pulmonary fibrosis. In: King TE Jr, ed. New approaches to managing idiopathic pulmonary fibrosis. San Francisco CA: American Thoracic Society 2000; S14-20.
21. Moser KM, Bokinski GE, Savage RT, Archibald CJ, Hansen PR. Results of a comprehensive rehabilitation program: physiologic and functional effects on patients with chronic obstructive pulmonary disease. Arch Intern Med 1980; 140: 1596-1601.
22. Scadding J. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after 5 years' observations. Br Med J 1961; 2: 1165-1172.
23. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG Statement on Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149-173.
24. Van Der Schoot JB, Goen AS, De Jong J. Gallium-67 scintigraphy in lung disease. Thorax 1972; 27: 543-546.
25. Gelb AF, Dreisen RB, Epstein JO, et al. Immune Complexes gallium in lung scans, and broncho alveolar lavage in idiopathic interstitial pneumonitis fibrosis. Chest 1983; 84: 148-153.
26. Cianci G, Sanguinetti CM, Maggi S, et al. 67-Ga scanning for evaluation activity in interstitial lung diseases. J Nucl Med Allied Sc. 1987; 31: 241-248.
27. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Eng J Med 1997; 336: 1224-1234.
28. Du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003; 253: 4-17.
29. Van Hagen PM. Somatostatin receptor expression in clinical immunology. Metabolism 1996; 45: 86-87.
30. Kwekkeboom DJ, Krenning EP, Kho GS, et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998; 25: 1284-1292.
31. King TE Jr. Idiopathic Pulmonary Fibrosis. In: In: Schwarz MI, King TE Jr, eds. Interstitial Lung Disease. Hamilton, Ontario: BC Decker Inc., 1998; 597-644.
32. Wagner HN Jr. Szabo Z, Buchanan JW eds: Principles of Nuclear Medicine, Second Edition. W.B. Saunders Company 1995; 1104-1110.
33. O'Connor MK. The Mayo Clinic Manual Of Nuclear Medicine. Churchill Livingstone 1996; 507-510.
34. Moeller DR. Systemic Sarcoidosis. In: Fishman AP, ed. Pulmonary disease and disorder's. New York, Mc Graw Hill, 1998; 1055-1068.
35. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. New Eng J Med 2001; 345: 517-525.
36. Lynch III JP Toews GB. Idiopathic pulmonary fibrosis. In: Fishman's A, ed. Pulmonary diseases and disorders. 3rd ed. New York, NY, 1998; 1069-1084.
37. Fallace MJ, Krishnamurthy S, Broemeling LD, et al. CT-guided percutaneous fine-needle aspiration biopsy of small (≤ 1-cm) pulmonary lesions. Radiology 2002; 225: 823-828.